Indole, a core nucleus for potent inhibitors of tubulin polymerization

Medicinal Research Reviews

Volumn 27, Issue 2, 2007, Pages 209-238

  Brancale, Andrea ^a   Silvestri, Romano ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti mitotic agents; Anti tumor drugs; Indoles; Tubulin

Indexed keywords

1 AROYLINDOLE; 2 AROYLINDOLE; 2 METHOXYESTRADIOL; 3 AROYLINDOLE; 3 FORMYL 2 PHENYLINDOLE DERIVATIVE; ANTIMITOTIC AGENT; COLCHICINE; COMBRETASTATIN A4; D 24851; DISCODERMOLIDE; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; ER 34410; HEMIASTERLIN; HETEROCOMBRESTATIN; INDOLE DERIVATIVE; LAULIMALIDE; MAYTANSINE; MIVOBULIN ISETHIONATE; MOROIDIN; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NSC 639829; OTTELIONE A; PACLITAXEL; RHIZOXINE; T 138067; THIOINDOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINFLUNINE;

CANCER; CANCER CELL CULTURE; CELL STRUCTURE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; MICROTUBULE ASSEMBLY; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; BIOCHEMISTRY; DRUG DESIGN; HUMANS; INDOLES; NERVE TISSUE PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 33847172794     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20080     Document Type: Review

References (60)

1. Downing KH, Nogales E. Tubulin and microtubule structure. Curr Opin Cell Biol 1998;10:16-22.
2. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;1:1-17.
3. Li Q, Sham HL. Discovery and development of antimitotic agents that inhibit tubulin polymerization for treatment of cancer. Exp Opin Ther Pat 2002;12:1663-1702.
4. Prinz H. Recent advances in the field of tubulin polymerization inhibitors. Exp Rev Anticancer Ther 2002;2:695-708.
5. Beckers T, Mahboobi S. Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy, and references therein. Drugs Fut 2003;28:767-785.
6. Owellen RJ, Owens AHJ, Donigian DW. The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 1972;47:685-691.
7. Pohle K, Matthies E, Peters JE. On the tumor growth-inhibiting action of cochicine. Arch Geschwulstforsh 1965;25:17-20.
8. Kingston DG. The chemistry of taxol. Pharm Ther 1991;52:1-34.
9. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667.
10. Hoefle G, Bedorf N, Steimetz H, Schomburg D, Gerth K, Reichenbach H. Epothilone A and B-Novel 16-membered macrolides with cytotoxic activity. Isolation, crystal structure and conformation in solution. Angew Chem Int Ed Engl 1996;35:1567-1569.
11. Corley DG, Herb R, Moore RE, Scheur PG, Paul VJ. Laulimalide. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J Org Chem 1988;53:3644-3646.
12. (a) Ter Haar E, Kowalski RJ, Hamel E, et al. Discodermolide, cytotoxyc marine agent that stabilizes microtubules more potently than Taxol. Biochemistry 1996;35:243-250.
13. (b) Paterson I, Florence GJ, Gerlach K, Scott JP, Sereinig N. A pratical synthesisi of (+)-discodermolide and analogues: Fragment union by complex aldol reactions. J Am Chem Soc 2001;23:9535-9544.
14. Hamel E, Covell DG. Antimitotic Peptides and Depsipeptides. Curr Med Chem Anticancer Ag 2002;2:19-53.
15. Duflos A, Kruczynski A, Barret J-M. Novel aspects of natural and modiflied Vinca alkaloids. Curr Med Chem Anticancer Agents 2002;2:55-70.
16. Kruczynski A, Hill BT. Vinflumine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001;40:159-173.
17. Mcintyre JA, Castaner J. Vinflumine: Antimitotic vinca alkaloid. Drugs Fut 2004;29:574-580.
18. Zhao S, Smith KS, Deveau AM, Dieckhaus CM, Johnson MA, Macdonald TL, Cook JM. Biological activity of Tryprostatins and their diastereoisomers on human carcinoma cell lines. J Med Chem 2002;45:1559-1562.
19. Usui T, Kondoh M, Cui CB, Mayumi T, Osada H. Tryprostatin A, a specific and novel inhibitor of microtubule assembly. Biochemical J 1998;333:543-563.
20. Morita H, Shimbo K, Shigemori H, Kobayashi J. Antimitotic activity of moroidin, a bicyclic peptide from the seeds of Celosia argentea. Bioorg Med Chem Lett 2000;10:469-471.
21. Kobayashi J, Suzuki H, Shimbo K, Takeya K, Morita H. Celogentins A-C, new antimitotic bicyclic peptides from the seeds of Celosia argentea. J Org Chem 2001;66:6626-6633.
22. 1,3-dimethyl- L-valinamide (HTI-286). J Med Chem 2004;47:4774-4786.
23. Lindquist N, Fenical W, van Duyne GD, Clardy J. Isolation and structure determination of diazonamides A and B, unusual cytotoxic metabolites from the marine ascidian Diazona chinensis. J Am Chem Soc 1991;113:2303-2304.
24. Cragg GM, Newman DJ. A tale of two tumor targets: Topoisoimerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 2004;67:232-244.
25. (a) Hamel E, Lin CM. Interactions of combretatstatin, a new plant-derived antimitotic agent with tubulin. Biochem Pharmacol 1983;32:3864-3867.
26. (b) Lin CM, Ho MM, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2. Studies on the mechanism of their inhibition of the binding of colchicine tu tubulin. Biochemistry 1998;28:6984-6991.
27. Shan B, Medina JC, Santha E, Frankmoelle WP, Chou TC, Learned RM, Narbut MR, Stott D, Wu P, Jaen JC, Rosen T, Timmermans PB, Beckmann H. Selective, covalent modification of beta-tubulin residue Cys239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Nat Acad Sci USA 1999;96:5686-5891.
28. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Nat Acad Sci USA 1994;91:3964-3968.
29. Van Belle SJ, Distelmans W, Vandebroek J, Bruynseels J, Van Ginckel R, Storme GA. Phase I trial of erbulozole (R55104). Anticancer Res 1993;13:2389-2391.
30. Haga T, Yamada N, Sugi H, Koyanagi T, Okada H, Ishihara Y. Preparation and formulation of (pyrimidinyloxyphenyl)benzoylureas as antitumor agents. Eur Pat Appl 1991; EP 413977.
31. Mounetou E, Legault J, Lacroix J, C-Gaudreault R. Antimitotic antitumor agents: Synthesis, structure-activity relationships, and biological characterization of N-aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents. J Med Chem 2001;44:694-702.
32. Yoshino H, Ueda N, Niijima J, Haneda T, Kotake Y, Yoshimatsu K, Watanabe T, Nagasu T, Tsukahara N, et al. Preparation of sulfonamide and sulfonic ester derivatives each having tricyclic heterocyclic ring as antitumor agents. PCT Int Appl 1995; WO9503279.
33. (a) Lisowski V, Enguehard C, Lancelot J-C, Caignard D-H, Lambel S, Leonce S, Pierre A, Atassi G, Renard P, Rault S. Design, synthesis and antiproliferative activity of tripentones: A new series of antitubulin agents. Bioorg Med Chem Lett 2001;16:2205-2208.
34. (b) Lisowski V, Leonce S, Kraus-Berthier L, Santos JS-de O, Pierre A, Atassi G, Caignard D-H, Renard P, Rault S. Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem 2004;47:1448-1464.
35. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E-7010, an orally active sulfonamide antitumor agents: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-3213.
36. Gastpar R, Goldbrunner M, Marko D, von Angerer E. Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem 1998;41:4965-4972.
37. Goldbrunner M, Loidl M, Polossek T, Mannschreck A, von Angerer E. Inhibition of tubulin polymerization by 5,6-5,6-dihydroindolo[2,1-a]isoquinoline derivatives. J Med Chem 1997;40:3524-3533.
38. Medarde M, Ramos A, Caballero E, Peláez-Lamamié de Clariac R, López JL, García Grávalos D, San Feliciano A. Synthesis and antineoplastic activity of combretastatin analogues, heterocombretastatins. Eur J Med Chem 1998;33:71-77.
39. Lin CM, Singh SB, Chu PS, Dempcey R, Smith JM, Petit GR, Hamel E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: A structure-activity study. Mol Pharmacol 1988;34:200-208.
40. Medarde M, Ramos AC, Caballero E, Peláez-Lamamié de Clariac R, López JL, García Grávalos D, San Feliciano A. Synthesis and pharmacological activity of diarylindole derivatives, cytotoxic agents based on combretastatins. Bioorg Med Chem Lett 1999;9:2303-2308.
41. Haar E, Rosenkranz HS, Hamel E, Day BW. Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. Bioorg Med Chem 1996;4:1659-1671.
42. Shi Q, Chen K, Morris-Natschke SL, Lee K-H. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Current Pharm Design 1998;4:219-248.
43. Mahboobi S, Pongratz H, Hufsky H, Hockenmeyer J, Frieser M, Lyssenko A, Paper DH, Burgmeister J, Böhmer F-D, Fiebig H-H, Burger AM, Baasner S, Beckers T. Synthetis 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J Med Chem 2001;44:4535-4553.
44. Beckers T, Reissmann T, Schmidt M, et al. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res 2002;62:3113-3119.
45. Knaack M, Emig P, Bats JW, Kiesel M, Müller A, Günther E. Synthesis and characterization of the biologically active 2-[1-(4-chlorobenzyl)- 1H-indol-3-yl]-2-oxo-N-pyridin-4-yl acetamide. Eur J Org Chem 2001;20:3843-3847.
46. Nickel B, Szelenyi S, Schmidt J, Emig P, Reichert D, Günther E, Brune K. Indol-3-yl-glyoxylsäure-derivate mit antitumorwirkung. Patent WO 51224, 1999.
47. Bacher G, Nickel B, Emig P, Vanhofer U, Seeber S, Shandra A, Klenner T, Beckers T. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vitro, shows efficacy toward multidrug-resistant tumor cells, and lacks neutoxicity. Cancer Res 2001;61:392-399.
48. Flynn BL, Hamel E, Jung MK. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J Med Chem 2002;45:2670-2673.
49. Arcadi A, Cacchi S, Marinelli F. A versatile approach to 2,3-disubstituted indoles through the palladium-catalyzed cyclization of o-alkynylfluoroacetanilides with vinyl triflates and aryl halides. Tetrahedron 1992;33:3915-3918.
50. Arcadi A, Cacchi S, Carnicelli V, Marinelli F. 2-Substituted-3- acylindoles through the palladium-catalyzed carbonilative cyclization of 2-alkynyltrifuoroacetanilides with aryl halides anf vinyl triflates. Tetrahedron 1994;50:437-452.
51. Liou J-P, Chang Y-C, Kuo F-M, Chang C-W, Tseng H-Y, Wang C-C, Yang Y-N, Chang J-Y, Lee S-J, Hsieh HP. Coincise synthesis and structure-activity relationships of combretastatins A-4 analogues, 1-aroylindoles and 3-aroylindoles, a novel class of potent antitubulin agents. J Med Chem 2004;47:4247-4257.
52. Liou J-P, Chang J-Y, Chang C-W, Chang CY, Mahindroo N, Kuo FM, Hsieh HP. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J Med Chem 2004;47:2897-2905.
53. Kuo C-C, Hsieh H-P, Pan W-Y, Chen C-P, Liou J-P, Lee S-J, Chang Y-L, Chen LT, Chen C-T, Chang J-Y. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral acitivity in vivo. Cancer Res 2004;64:4621-4628.
54. De Martino G, La Regina G, Coluccia A, Edler MC, Barbera MC, Brancale A, Wilcox E, Hamel E, Artico M, Silvestri R. Arylthioindoles, potent inhibitors of tubulin polymerization. J Med Chem 2004;47:6120-6123.
55. Flynn BL, Flynn GP, Hamel E, Jung MK. The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg Med Chem Lett 2001;11:2341-2343.
56. Flynn BL, Hamel E, Jung MK. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. J Med Chem 2002;45:2670-2673.
57. Yamamoto K, Noda K, Yoshimura A, Kukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chem Pharmacol 1998;42:124-134.
58. Atkinson JG, Hamel P, Girard YA. A new synthesis of 3-arylthioindoles. Synthesis 1988;480-481.
59. De Martino G, Edler MC, La Regina G, Coluccia A, Barbera MC, Barrow D, Nicholson RI, Chiosis G, Brancale A, Hamel E, Artico M, Silvestri R. New arythioindoles, potent inhibitors of tubulin polymerization. 2. Structure activity relationship and molecular modeling studies. J Med Chem 2006;49:947-954.
60. Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202.